{"filings":[{"id":69762,"accession_number":"0001140361-26-021081","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2026-05-13T20:48:01+00:00","items":["7.01","9.01"],"status":"ready","headline":"Femasys posts updated investor presentation; no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide deck highlights Femasys's reproductive health products and pipeline.","No financial guidance, earnings, or operational metrics disclosed.","Presentation available on company website for investor meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92317,"accession_number":"0001140361-26-020059","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys reports Q1 net income of $846K; sales up 24.5%; cash sufficient into Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $846,100 ($0.00 per diluted share) vs net loss $5.9M ($0.23 loss) in prior year; net income includes $5.2M in gains from fair value changes.","Sales rose 24.5% to $424,889, driven by FemBloc sales; R&D expenses down 55.9% to $1.31M.","Cash $5.4M as of March 31; company expects funding into Q3 2026 based on current operating plan.","Advanced FemaSeed Complete commercialization; initiated FINALE pivotal trial for FemBloc non-surgical birth control.","Appointed John Canning as COO; added Kenneth D. Eichenbaum to board; MDSAP certification for FemBloc."],"consensus_eps_estimate":-0.0918,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":424889.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92316,"accession_number":"0001140361-26-017805","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Femasys shareholders approve reverse stock split (1:2 to 1:25) and anti-dilution share issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split authorized by board at ratio of 1-for-2 to 1-for-25, with discretion until May 1, 2027; votes: 18.9M For, 5.2M Against.","Share issuance for anti-dilution provisions under Nov 2025 SPA and Mar 2026 amendment approved; votes: 7.5M For, 1.7M Against, 14.9M broker non-votes.","Both proposals passed; adjournment proposal not presented due to sufficient votes.","Special Meeting held April 29, 2026; ~39.91% of outstanding shares were represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92315,"accession_number":"0001140361-26-012538","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Femasys appoints John Canning as COO; base $450K, inducement option 150K shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Canning appointed COO effective March 30, 2026; annual base salary $450,000 with 40% target bonus.","Canning previously COO at Terumo Aortic (2017-2026) and Bolton Medical, with 25+ years MedTech experience.","Granted inducement stock option for 150,000 shares at closing price on grant date; vesting 25% annually over 4 years.","Appointment aims to strengthen operational capabilities and support commercial growth of FemBloc and FemaSeed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103085,"accession_number":"0001140361-26-012346","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys reports 2025 revenue up 40.8% to $2.3M; net loss $18.6M; cash into Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue increased 40.8% to $2,293,313 in 2025 from $1,629,108 in 2024, driven by FemBloc sales.","Net loss was $18,627,887 ($0.47 per share) vs $18,816,628 ($0.85 per share) in 2024; EPS improved on share count increase.","Cash and cash equivalents $9.3M as of Dec 31, 2025; expects to fund operations into Q3 2026.","Initiated patient enrollment in FINALE pivotal trial for FemBloc; received MDSAP certification.","Completed $12M financing in late 2025; appointed Kenneth D. Eichenbaum to Board."],"consensus_eps_estimate":-0.0918,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":424889.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103084,"accession_number":"0001140361-26-010591","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Femasys amends convertible notes, removes anti-dilution, issues 16.4M warrants at $0.58; board adds director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Omnibus Amendment removes Share Combination Event Adjustment from $10.5M+ senior secured convertible notes and warrants, effective Dec 31, 2025.","As consideration, lenders receive 16,378,563 Series D-1 Warrants exercisable at $0.58 per share (Nasdaq minimum price on March 19, 2026).","Director Joshua Silverman resigned March 17, 2026; no disagreement. Board appointed Kenneth D. Eichenbaum, M.D., effective March 18, 2026.","Amendment expands Securities Purchase Agreement participation right exclusion to cover Series D-1 Warrants and underlying shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103083,"accession_number":"0001140361-26-001268","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Femasys granted 180-day extension to cure Nasdaq minimum bid price deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice July 16, 2025; bid price below $1.00 for 30 consecutive days.","Granted extension to July 13, 2026 after requesting 180-day extension on Jan 12, 2026.","Company reported stockholders' equity over $5M as of Dec 31, 2025; plans reverse stock split if needed.","Common stock ticker FEMY remains listed on Nasdaq Capital Market during extension period.","Non-compliance continues; risk of delisting if not cured by July 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119321,"accession_number":"0001140361-25-046546","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys files prospectus for ATM offering of up to $9.8M common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement filed Dec 23, 2025 for sale of up to $9.8M in common stock under existing equity distribution agreement.","Shares sold through Piper Sandler & Co. as sales agent in at-the-market offerings at Company's discretion.","Offering utilizes effective shelf registration statement on Form S-3 (File No. 333-288527).","Proceeds intended for general corporate purposes; no specific use stated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119320,"accession_number":"0001140361-25-045950","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys receives FDA 510(k) clearance for next-gen FemVue Controlled device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA 510(k) clearance for FemVue Controlled, integrating FemVue and FemChec technologies.","Single-device solution for controlled contrast delivery to evaluate fallopian tube status.","Designed to enable multiple clinical uses and streamline manufacturing and practice workflows.","CEO Kathy Lee-Sepsick highlights milestone as advancing clinician-focused innovations.","NASDAQ-ticker FEMY; clearance announced December 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119319,"accession_number":"0001140361-25-042304","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys Q3 sales up 31% to $729K; FDA clears FemBloc final pivotal trial; $12M financing extends runway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.19M ($0.10/sh) vs $5.41M ($0.24/sh) a year ago on lower R&D spend.","Sales rose 31.4% YoY to $729,394, driven by FemBloc product sales.","FDA IDE approval to commence final phase of FemBloc pivotal trial for U.S. approval.","Closed $12M secured convertible note offering with warrants for up to $58M total potential funding.","Cash $4.6M at Q3 end; with recent financing, runway extended into September 2026."],"consensus_eps_estimate":-0.1326,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":1479926.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119318,"accession_number":"0001140361-25-041293","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys receives second $500k FemBloc order from Kebomed for Europe","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Order valued at ~$500k for commercial launch of FemBloc in France and Benelux region.","Kebomed, a leading distributor, placed the order following Femasys' recent entry into Spain.","FemBloc is a non-surgical permanent contraceptive using a patented polymer to occlude fallopian tubes.","CEO Kathy Lee-Sepsick cited strategic partnerships driving international expansion and shareholder value.","No anesthesia, incisions, or recovery time required; addresses unmet need in reproductive health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119317,"accession_number":"0001140361-25-041180","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Femasys raises $12M via senior secured convertible notes and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Senior secured convertible notes: $12M aggregate principal, 8.5% interest (PIK), conversion price $0.73 (15% premium to close), 10-year maturity.","Series A-1/B-1/C-1 warrants at $0.81/$0.92/$1.10 exercise prices, expiring 10 years (some subject to early expiry based on sales or FDA approval).","Proceeds to repay existing $12M Nov 2023 senior notes and for working capital; first closing Nov 7, second Nov 26, 2025.","CEO Kathy Lee Sepsick, CFO, and board member purchased $100k of notes/warrants on same terms as other investors.","Lead lender Pointillist Global Macro receives board nomination right until ownership <4.99% or 5 years; standstill at 30%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119316,"accession_number":"0001140361-25-040104","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys gets FDA IDE approval for FemBloc final trial phase, secures $12M financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA IDE approval to continue enrollment in Part B of FINALE pivotal trial for FemBloc non-surgical permanent birth control.","$12M senior secured convertible notes issued with potential total proceeds of $58M if all warrants exercised.","Notes bear 8.5% interest, 10-year maturity, convertible at $0.73/share (15% premium to last close).","Warrants issued at exercise prices of $0.81, $0.92, and $1.10 per share, each for 16.4M shares.","Proceeds to refinance debt and advance commercialization of fertility and birth control portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119315,"accession_number":"0001140361-25-038733","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Femasys updates Nasdaq compliance; pro forma equity ~$5.2M meets $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received prior Nasdaq deficiency notice for MVLS below $35M and failure to meet alternative listing standards.","After $8M August 2025 offering and warrant exercises, pro forma stockholders' equity ~$5.2M as of Oct 15, 2025.","Company believes it now satisfies $2.5M minimum equity requirement for continued Nasdaq listing.","Nasdaq will continue monitoring; failure to evidence compliance at next periodic report may trigger delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119314,"accession_number":"0001140361-25-038516","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Femasys COO Daniel Currie to retire effective Dec 15, 2025; equity awards vest through retirement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Currie, COO since March 2004, retiring effective Dec 15, 2025 for personal health reasons.","Unvested stock options will vest through the retirement date; health benefits through COBRA until Dec 31, 2026.","Separation agreement includes standard non-competition, non-solicitation, and confidentiality covenants.","Currie will remain in his current role until his departure date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135891,"accession_number":"0001140361-25-032806","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Femasys announces $8.0M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 10,434,586 shares of common stock, pre-funded warrants for 11,750,000 shares, and common warrants for 22,184,586 shares at combined price $0.36 per unit.","Gross proceeds expected to be $8.0 million; closing expected August 27, 2025.","Pre-funded warrants exercisable immediately at $0.0001; common warrants exercisable at $0.36 for 5 years.","Officers purchase shares at $0.5151 and receive common warrants with $0.5151 exercise price.","Proceeds to be used for commercial expansion, product development, working capital, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135890,"accession_number":"0001140361-25-032014","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys secures UK MHRA approval for FemBloc permanent birth control","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MHRA approval validates safety, quality, and effectiveness for UK market.","Follows CE mark for Europe; expands global commercialization strategy.","FemBloc is a non-surgical polymer that forms scar tissue for permanent occlusion.","UK's NHS offers pathway to broad adoption for innovative women's health solutions.","Company plans to secure a strategic partner for UK commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135889,"accession_number":"0001140361-25-029860","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys Q2 2025 sales up 85% to $409K, net loss $4.6M, cash runway into early Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $409,268 (+84.8% YoY); net loss $4.59M ($0.16/sh) vs $4.68M ($0.21/sh) prior year.","Cash $3.2M, accumulated deficit $137.7M; expects current cash to fund ops into early Q4 2025.","EU MDR approval for FemBloc non-surgical birth control; first $400K order from Spain.","Australia/New Zealand approvals for FemaSeed and FemVue; partnered with Carolinas Fertility Institute.","Closed $4.5M public offering and private placement for working capital."],"consensus_eps_estimate":-0.1836,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":750532.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135888,"accession_number":"0001140361-25-029065","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys secures first European order for FemBloc in Spain, approximately $400,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First commercial European order for FemBloc permanent birth control valued at ~$400,000 USD.","Distribution partners in Spain: Comercial Medico Quirúrgica and Durgalab.","FemBloc is a non-surgical polymer that degrades to form scar tissue for permanent occlusion.","Company focused on scaling production to meet anticipated European demand.","Spain is the first country globally to offer FemBloc outside the US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135887,"accession_number":"0001140361-25-026431","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Femasys receives Nasdaq minimum bid price non-compliance notice; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Femasys on July 16, 2025, of non-compliance with $1.00 minimum bid price for 30 consecutive business days.","Company has until January 12, 2026, to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not cured, Femasys may qualify for an additional 180-day period if it meets other initial listing standards.","Management may consider a reverse stock split to cure the deficiency; no immediate impact on trading.","Failure to regain compliance could lead to delisting; the company can appeal any delisting determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135886,"accession_number":"0001140361-25-024878","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Femasys enters $10M equity purchase agreement with Alumni Capital LP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $10M of common stock may be sold to Alumni Capital at Company's election through Dec. 31, 2026.","Pricing at 90% of lowest 4-day traded price (Option 1) or 97% of 2-day VWAP (Option 2).","Commitment fee of 2% ($200,000) to be paid in cash or shares, likely in cash.","Registration statement on Form S-1 must be filed by July 30, 2025 and effective within 120 days.","Purchaser limited to 4.99% beneficial ownership; may be increased to 9.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135885,"accession_number":"0001140361-25-024313","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys gets Australian & New Zealand approvals for FemaSeed and FemVue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regulatory approvals granted for FemaSeed first-line intratubal insemination treatment and FemVue diagnostic.","CEO Kathy Lee-Sepsick cites expanded global access and meaningful commercial opportunities.","Approvals validate clinical value of platform and reinforce commitment to accessible infertility solutions.","Company expects to grow revenue and broaden global footprint with these regulatory milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152877,"accession_number":"0001140361-25-023642","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Femasys stockholders elect directors, approve equity plan amendment, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alistair Milnes elected with 4,882,989 votes for; Edward Uzialko with 4,947,997 votes for.","Amendment to 2021 Equity Incentive Plan approved, increasing authorized shares by 3,000,000 (4,257,199 for, 1,582,147 against).","Ratification of KPMG as independent auditor for FY2025 passed with 16,103,557 votes for.","Turnout: 16,183,538 shares voted, approx. 59.41% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152876,"accession_number":"0001140361-25-023561","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys receives CE mark for FemBloc, first non-surgical permanent birth control, for European market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CE mark certification for entire FemBloc System under EU MDR 2017/745; can now be marketed in European Economic Area (27 EU + 3 EFTA states).","Follows earlier March 13, 2025 delivery system approval; combined approval marks first global regulatory endorsement.","Company plans initial commercial launch in Spain via existing distribution partnerships; also seeking additional country approvals.","FemBloc is a non-surgical permanent birth control alternative; U.S. FDA IDE pivotal trial continues enrollment for U.S. approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152875,"accession_number":"0001140361-25-022762","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys appoints Kelley Nicholas as CCO; grants 100,000-share inducement option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Kelley Nicholas as Chief Commercial Officer effective June 17, 2025; she will lead U.S. commercialization and global partnerships.","Nicholas brings over 25 years experience from NeuroPace, Hologic, Medtronic, Baxter, Intuitive Surgical.","As inducement, Femasys granted option to purchase 100,000 shares vesting over 4 years (25% after 1 year, then 25% annually).","Focus on expanding U.S. infertility market for FemaSeed and building international partnerships across full portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152874,"accession_number":"0001140361-25-021030","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Femasys raises $4.5M in combined underwritten public offering and concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 3.6M shares at $0.85/share; underwriter granted 30-day option for 540k additional shares.","Concurrent private placement: ~1.7M shares sold to existing institutional stockholders ($0.85) and directors/officers ($1.02).","Net proceeds expected ~$4.2M; intended for commercial expansion, product development, working capital.","Company also agreed to enter $10M equity line of credit with Alumni Capital LP by June 30, 2025; otherwise $400k liquidated damages.","Underwriter receives warrants to purchase 105,726 shares at $1.0625, exercisable after six months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152873,"accession_number":"0001140361-25-020363","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Femasys receives Nasdaq delisting notice for MVLS below $35M; 180-day cure period until Nov 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Femasys MVLS of common stock was below $35M minimum for 30 consecutive business days.","Femasys also fails alternative listing standards: stockholders' equity <$2.5M or net income <$500k.","Company has 180 calendar days, until November 17, 2025, to regain compliance.","No immediate effect on listing; Femasys will monitor MVLS and consider options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152872,"accession_number":"0001140361-25-017983","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys Q1 sales up 25.9% but net loss widens to $5.9M; cash runway only into early Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales increased 25.9% YoY to $341K, driven by FemaSeed sales.","Net loss widened to $5.9M ($0.23 per share) from $3.6M ($0.17) in prior year.","R&D expenses surged 67.6% to $2.97M, mainly due to regulatory and development costs.","Cash and equivalents $3.8M; company expects to fund operations only into early Q3 2025.","FemBloc delivery system received CE mark recommendation in Europe; FemaSeed partnerships expanded."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":341264.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171685,"accession_number":"0001140361-25-010595","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys reports 52% revenue growth in 2024; net loss widens to $18.8M; cash runway into Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.63M, up 52% YoY; net loss $18.8M ($0.85/sh) vs $14.2M ($0.93/sh) in 2023.","Cash $3.5M at year-end; subsequent $5.4M raise; expects runway into Q3 2025.","R&D $8.2M (+14%) and sales/marketing $4.0M (6x increase) due to FemBloc/FemaSeed launch.","FemBloc received European approval; partnerships with CNY Fertility, HRC Fertility, Boston IVF for FemaSeed.","CEO guides U.S. revenue to increase ~50% in Q1 2025 vs Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171684,"accession_number":"0001140361-25-009177","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys secures first EU distribution partners in Spain for FemBloc birth control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partners are Comercial Medico Quirurigca (northern Spain) and Durgalab (southern Spain).","Both distributors previously commercialized Conceptus Essure, a non-surgical permanent birth control product.","This marks FemBloc's first entry into the European market via distribution partnerships.","CEO Kathy-Lee Sepsick called the milestone 'significant' in expanding innovative women's health technologies globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171683,"accession_number":"0001140361-25-008559","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys gets CE mark for FemBloc delivery system in Europe, polymer approval expected mid-2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FemBloc delivery system receives first-in-world CE mark certification under EU MDR for non-surgical permanent birth control.","FemBloc blended polymer completes G12 Special MDR Audit; Notified Body recommends CE mark pending EMA review, approval expected mid-2025.","Company continues enrolling participants in FDA IDE-approved pivotal clinical trial for U.S. approval of FemBloc.","CEO Kathy Lee-Sepsick highlights FemBloc as a safer, accessible alternative to surgical sterilization, the only option today."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188679,"accession_number":"0001140361-24-046034","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales in Q3.","Net loss $5.4M ($0.24/share) vs $4.0M ($0.26/share) in Q3 2023.","Cash $7.6M; expects runway into July 2025.","Announced partnerships with Boston IVF and Spain distributors; Spain deals expected >$1.3M over next year.","Received FDA clearance for FemChec, CE mark for FemVue MINI, and patent for FemBloc."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1047532.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188677,"accession_number":"0001140361-24-046158","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K/A","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales recorded.","Net loss $5.4M ($0.24/share) vs $4.0M ($0.26) in Q3 2023; cash $7.6M.","Cash runway expected into July 2025 based on current operating plan.","Partnerships with Boston IVF, Spain distributors; FDA clearance for FemChec; CE Mark for FemVue MINI."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1047532.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188678,"accession_number":"0001140361-24-044486","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Femasys posts updated October 2024 investor presentation; no financial updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made updated slide presentation available on its website for use in meetings with investors and analysts.","Presentation reiterates focus on women's reproductive health innovation; no new financial guidance or material events disclosed.","No specific numbers, new product approvals, or changes to outlook were included in the available excerpt.","Filing is routine; confidence is low due to lack of full presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205143,"accession_number":"0001140361-24-040780","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys secures Spain distribution deals with $1.3M minimum FemaSeed purchase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partners CMQ (northern Spain) and Durgalab (southern Spain) to distribute FemaSeed and FemVue.","Minimum purchase commitment of $1.3M for FemaSeed over the next year from the two distributors.","Spain is the first EU country where Femasys has identified distributors and begun marketing its CE-marked products.","CEO Kathy Lee-Sepsick highlights global expansion and affordable infertility solutions as key strategic moves."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205142,"accession_number":"0001140361-24-040514","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys receives FDA 510(k) clearance for FemChec fallopian tube diagnostic","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FemChec cleared by FDA for controlled contrast delivery to check tubal status.","FemChec is also used as confirmation test after FemBloc non-surgical permanent birth control.","FemBloc is in late-stage FINALE pivotal trial, currently enrolling.","FemChec uses natural contrast and ultrasound, avoiding x-ray dye and radiation exposure.","CEO Kathy Lee-Sepsick says clearance strengthens women's health product suite."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205141,"accession_number":"0001140361-24-039777","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Femasys posts updated investor presentation; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted an updated slide presentation on its website for use in meetings with investors and analysts.","Presentation dated August 30, 2024, furnished as Exhibit 99.1; content is not deemed filed for SEC purposes.","Exhibit text truncated in filing; no specific financial or operational data available for summary.","No new earnings, guidance, or business developments were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205140,"accession_number":"0001140361-24-039138","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys receives CE Mark and Health Canada approval for FemVue MINI fallopian tube assessment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CE Mark certification obtained for FemVue MINI, enabling sales in European Economic Area.","Health Canada granted product approval for FemVue MINI, opening Canadian market.","FemVue MINI is a compact, eco-friendly version of existing FemVue diagnostic product.","CEO Kathy Lee-Sepsick cites expanded access to advanced women's health diagnostics in Europe and Canada.","Product designed with smaller environmental footprint, supporting company sustainability initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205139,"accession_number":"0001140361-24-036294","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys Q2 2024 revenue down 31% YoY to $221K; net loss widens to $4.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 sales of $221,484, down 31% from $320,514 in Q2 2023.","Net loss of $4.68M ($0.21 per share) compared to $2.89M ($0.22 per share) a year ago.","Cash and cash equivalents $13.5M; expects to fund operations into July 2025.","Received CE Mark for four women's health products; completed U.S. commercial team build-out."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":492624.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205138,"accession_number":"0001140361-24-033049","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Femasys annual meeting elects Kathy Lee-Sepsick as Class III director, ratifies KPMG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kathy Lee-Sepsick elected as Class III director with 3,943,064 votes for, 589,253 against, 71,779 abstained, and 6,099,540 broker non-votes.","Ratification of KPMG LLP as independent auditor for FY2024 approved: 10,670,335 for, 33,301 against, 0 abstentions.","Annual meeting turnout: 10,703,636 shares represented (48.2% of outstanding shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222026,"accession_number":"0001140361-24-030638","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Femasys receives CE Mark for four women's health products, enters EU market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received EU MDR certificate and CE Mark for FemaSeed, FemVue, FemCerv, FemCath.","Approvals allow Femasys to begin marketing all four products in the European Union.","CEO Kathy Lee-Sepsick: CE Mark validates commitment to highest quality and safety standards.","Company will identify strategic distribution partners to commercialize products throughout the EU.","Initial US commercial team build-out completed; EU expansion follows CE Mark approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222025,"accession_number":"0001140361-24-025064","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Femasys Q1 net loss widens to $3.6M; sales down 8%; cash runway into H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.6M ($0.17 EPS) vs $2.9M ($0.25 EPS) in Q1 2023; sales $271K vs $294K.","R&D expenses rose 15% to $1.77M; G&A $1.50M; operating loss $3.46M.","Cash $17.8M; expects funding operations into second half 2025.","Positive topline data from FemaSeed pivotal trial; first commercial procedure completed.","Appointed Richard Spector as CCO; FemBloc pivotal trial enrollment initiated at six sites."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":271140.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222024,"accession_number":"0001140361-24-021613","cik":1339005,"company_name":"FEMASYS INC","ticker":"FEMY","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Femasys posts updated corporate presentation on investor website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation available on company website for use in investor meetings.","No material financial data or guidance changes disclosed in the filing or excerpt.","Company continues to focus on women's reproductive health innovation.","No forward-looking statements or updated projections provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22199615.874074075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}